BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 17,000 Shares

Key Points

• BioNTech CEO Ugur Sahin sold 17,000 shares at an average price of $97.46, generating $1.66 million. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, leaving him with 197,209 shares.
• Sahin has conducted a series of stock sales in recent weeks, selling more than 300,000 shares across the disclosed transactions.
• BioNTech shares traded near $96.90, while the company recently reported a quarterly loss of $2.53 per share and revenue of $122.31 million, missing analyst expectations. Analysts maintain a consensus “Moderate Buy” rating with a $126 price target.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 17,000 shares of BioNTech stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00. Following the sale, the chief executive officer owned 197,209 shares in the company, valued at $19,219,989.14. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.

BioNTech Stock Performance

NASDAQ BNTX traded up $0.05 during trading on Friday, hitting $96.90. 681,351 shares of the company's stock traded hands, compared to its average volume of 1,087,641. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a market capitalization of $24.50 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The business has a 50 day moving average of $98.66 and a 200-day moving average of $94.99.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech's revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.60) EPS. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Flossbach Von Storch SE bought a new stake in shares of BioNTech during the 2nd quarter worth $207,142,000. Bank of America Corp DE increased its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. First Trust Advisors LP increased its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after acquiring an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in BioNTech during the second quarter valued at about $39,385,000. Finally, CenterBook Partners LP raised its position in BioNTech by 27.3% during the fourth quarter. CenterBook Partners LP now owns 236,175 shares of the company's stock valued at $22,484,000 after purchasing an additional 50,684 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Morgan Stanley decreased their price target on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 8th. Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research note on Wednesday, September 16th. Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group decreased their price target on shares of BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.